Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and half year ended September 30, 2026
Nature of Filing / Announcement: Outcome of Board Meeting
Audit Opinion:
Unmodified conclusion (clean opinion) from statutory auditors MSK A & Associates LLP for both standalone and consolidated financial results
Key Financial Highlights [₹ in million]:
Standalone Results:
Revenue from Operations: Q2 FY27: ₹1,371.68; H1 FY27: ₹2,530.25
Total Income: Q2 FY27: ₹1,535.65; H1 FY27: ₹2,717.09
Net Profit: Q2 FY27: ₹417.05; H1 FY27: ₹640.51
EPS: Q2 FY27: ₹3.74 (Basic), ₹3.73 (Diluted); H1 FY27: ₹5.73 (Basic), ₹5.72 (Diluted)
Other Equity: ₹6,862.66 million as of September 30, 2026
Cash and Cash Equivalents: ₹38.87 million as of September 30, 2026
Debt: Not specifically disclosed in standalone results
Consolidated Results:
Revenue from Operations: Q2 FY27: ₹2,145.09; H1 FY27: ₹4,062.17
Total Income: Q2 FY27: ₹2,232.29; H1 FY27: ₹4,260.38
Net Profit: Q2 FY27: ₹511.53; H1 FY27: ₹897.42
EPS: Not specifically disclosed in consolidated results
Other Equity: ₹16,427.38 million as of September 30, 2026
Cash and Cash Equivalents: ₹1,587.63 million as of September 30, 2026
Debt: Non-current borrowings ₹87.32 million; Current borrowings ₹130.18 million
Segment-wise Performance:
The Group operates only in one business segment viz manufacturing and sales of enzymes
Corporate Actions:
Dividend: Final dividend for FY 2025-26 of ₹1.35 per equity share was paid on August 5, 2026
Buyback: Board approved buyback of up to ₹697 million at maximum price of ₹500 per share. As of October 30, 2026, bought back 2,410,906 equity shares utilizing ₹696.96 million (99.99% of approved size)
Other Significant Information:
The consolidated results include 14 subsidiaries and 1 associate company
Company incorporated new wholly owned subsidiary Advanced Nutrazyme Private Limited on July 4, 2025
Exceptional items related to labor code implementation impacts were recorded in FY26 results